1-7 of 7
Yuan Qi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Xin Hua, Xi-Wen Bi, Jian-Li Zhao, Yan-Xia Shi, Ying Lin, Zhi-Yong Wu, Yuan-Qi Zhang, Le-Hong Zhang, An-Qing Zhang, Heng Huang, Xin-Mei Liu, Fei Xu, Ying Guo, Wen Xia, Ruo-Xi Hong, Kui-Kui Jiang, Cong Xue, Xin An, Yong-Yi Zhong, Shu-Sen Wang, Jia-Jia Huang, Zhong-Yu Yuan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 637–645.
https://doi.org/10.1158/1078-0432.CCR-21-3435
Published: 15 February 2022
View article titled, Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Open the PDF for Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002) in another window
Includes: Supplementary data
Journal Articles

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation

Daniela Asslaber, Nathalie Wacht, Michael Leisch, Yuan Qi, Nicole Maeding, Clemens Hufnagl, Bettina Jansko, Nadja Zaborsky, Andreas Villunger, Tanja N. Hartmann, Richard Greil, Alexander Egle
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1901–1912.
https://doi.org/10.1158/1078-0432.CCR-18-1548
Published: 15 March 2019
View article titled, BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation
Open the PDF for BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation in another window
Includes: Supplementary data
Journal Articles

Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer

Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, W. Fraser Symmans
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (20): 5265–5271.
https://doi.org/10.1158/1078-0432.CCR-14-0800
Published: 14 October 2014
View article titled, Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Open the PDF for Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

Charles Coutant, Roman Rouzier, Yuan Qi, Jacqueline Lehmann-Che, Giampaolo Bianchini, Takayuki Iwamoto, Gabriel N. Hortobagyi, W. Fraser Symmans, Serge Uzan, Fabrice Andre, Hugues de Thé, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2591–2601.
https://doi.org/10.1158/1078-0432.CCR-10-1045
Published: 14 April 2011
View article titled, Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Open the PDF for Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

Adel Tabchy, Vicente Valero, Tatiana Vidaurre, Ana Lluch, Henry Gomez, Miguel Martin, Yuan Qi, Luis Javier Barajas-Figueroa, Eduardo Souchon, Charles Coutant, Franco D. Doimi, Nuhad K. Ibrahim, Yun Gong, Gabriel N. Hortobagyi, Kenneth R. Hess, W. Fraser Symmans, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5351–5361.
https://doi.org/10.1158/1078-0432.CCR-10-1265
Published: 31 October 2010
View article titled, Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
Open the PDF for Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer

Jae K. Lee, Charles Coutant, Young-Chul Kim, Yuan Qi, Dan Theodorescu, W. Fraser Symmans, Keith Baggerly, Roman Rouzier, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 711–718.
https://doi.org/10.1158/1078-0432.CCR-09-2247
Published: 14 January 2010
View article titled, Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer
Open the PDF for Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Defective Expression of Transforming Growth Factor β Receptor Type II Is Associated with CpG Methylated Promoter in Primary Non-Small Cell Lung Cancer

Hong-Tao Zhang, Xiao-Feng Chen, Ming-Hua Wang, Jiu-Cun Wang, Qing-Yuan Qi, Rong-Mei Zhang, Wei-Qing Xu, Qing-Yan Fei, Fei Wang, Qi-Qun Cheng, Feng Chen, Cheng-Song Zhu, Shi-Heng Tao, Zewei Luo
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2359–2367.
https://doi.org/10.1158/1078-0432.CCR-0959-3
Published: 08 April 2004
View article titled, Defective Expression of Transforming Growth Factor β Receptor Type II Is Associated with CpG Methylated Promoter in Primary Non-Small Cell Lung Cancer
Open the PDF for Defective Expression of Transforming Growth Factor β Receptor Type II Is Associated with CpG Methylated Promoter in Primary Non-Small Cell Lung Cancer in another window